Sun Pharmaceutical Industries Ltd. has announced the acquisition of Innovcare Lifesciences Private Limited. The deal, valued at approximately ₹271.2 crore, will give Sun Pharma complete ownership of the Mumbai-based healthcare company.

The Subject Expert Committee (SEC) on Antimicrobial & Antiparasitic has asked M/s Emcure Pharmaceuticals Limited to revise its proposed Active Post-Marketing Surveillance (PMS) protocol for Liposomal Amphotericin B Injection 50 mg/vial (Lyophilized) before it can be considered further.

The recommendation was made during the 6th SEC (Antimicrobial & Antiparasitic) meeting of 2026, held on June 11, 2026, at the Central Drugs Standard Control Organization (CDSCO) headquarters in New Delhi.

In a significant development in the biosimilar segment, the Subject Expert Committee (SEC) on Dermatology & Allergy has recommended granting permission to M/s Kemwell Biopharma Private Limited to conduct a comparative pharmacokinetic clinical study for its proposed Dupilumab biosimilar, ASP100.

The recommendation was made during the 6th SEC (Dermatology & Allergy) meeting of 2026, held on June 11, 2026, at the CDSCO Headquarters in New Delhi.

The Govt. of India have created a separate, dedicated, autonomous institution in the form of the Indian Pharmacopoeia Commission (IPC) to deal with matters relating to timely publication of the Indian Pharmacopoeia which is the official book of standards for drug included therein, in terms of the Second Schedule to the Drugs and Cosmetics Act, 1940 so as to specify the standards of identify, purity and strength of the drugs imported, manufactured for sale, stocked or exhibited for sale or distributed in India.